U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545759) titled 'A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)' on April 16.
Brief Summary: The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.
The study will last approximately 35 weeks.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Irritable Bowel Syndrome
Diarrhea
Intervention:
DRUG: LY3537031
Administered SC
D...